← Leaderboards
Andrew McGuire
Fred Hutchinson Cancer Center
$8,683,437
Attributed
$9,707,262
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,707,262 · 6
By mechanism
R01$5,256,061 · 2
P01$1,947,463 · 1
U01$1,535,738 · 1
R21$968,000 · 2
Top collaborators
- Jim Boonyaratanakornkit2 shared
- Warren Phipps2 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Leonidas A Stamatatos$77,152,738
- Roland Bruno Walter$12,142,218
- Warren Phipps$6,635,898
- Jim Boonyaratanakornkit$2,850,119
Others in their field
Top investigators on “Epitopes”
- Lawrence Corey · Fred Hutchinson Cancer Center$261,200,380
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$255,239,983
- Dennis R. Burton · Scripps Research Institute$109,374,382
- Barton F Haynes · Duke University$108,968,244
- Alessandro Sette · La Jolla Institute For Immunology$86,747,756
- Dan H. Barouch · Fred Hutchinson Cancer Center$81,679,346
Research focus
EpitopesImmune ResponseBindingMonoclonal AntibodiesAntibodiesNeutralizing AntibodyB-LymphocytesVaccinesHumanized MouseInfectionRecombinantsNovel VaccinesMouse ModelHiv-1DesignAnimal ModelGlycoproteinsSiteViralIn VitroSpecificityAntigensS LymphomaAnimals
Grant awards (21)
Defining Critical Sites of Vulnerability and Correlates of Protection to Kaposi Sarcoma Associated Herpesvirus to Inform Vaccine Design$768,047
U01 · FY2025 · CA · contact PI
Rational Vaccine Design to prevent HIV-Associated Lymphoma$647,437
R01 · FY2025 · CA · contact PI
Defining Critical Sites of Vulnerability and Correlates of Protection to Kaposi Sarcoma Associated Herpesvirus to Inform Vaccine Design$767,691
U01 · FY2024 · CA · contact PI
Rational Vaccine Design to prevent HIV-Associated Lymphoma$664,754
R01 · FY2024 · CA · contact PI
Defining the protective efficacy of antibodies against the EBV gH/gL glycoprotein complex$763,782
R01 · FY2023 · AI · contact PI
Evaluating anti-idiotypic antibodies as novel vaccine candidates against HIV-1$369,104
P01 · FY2023 · AI · contact PI
Defining the protective efficacy of antibodies against the EBV gH/gL glycoprotein complex$763,782
R01 · FY2022 · AI · contact PI
Evaluating anti-idiotypic antibodies as novel vaccine candidates against HIV-1$263,209
P01 · FY2022 · AI · contact PI
Development of an anti-idiotype based vaccine for respiratory syncytial virus$220,000
R21 · FY2022 · AI · contact PI
Evaluating anti-idiotypic antibodies as novel vaccine candidates against HIV-1$117,329
P01 · FY2022 · AI · contact PI
Defining the protective efficacy of antibodies against the EBV gH/gL glycoprotein complex$432,778
R01 · FY2021 · AI · contact PI
Evaluating anti-idiotypic antibodies as novel vaccine candidates against HIV-1$418,203
P01 · FY2021 · AI · contact PI
Defining the protective efficacy of antibodies against the EBV gH/gL glycoprotein complex$392,604
R01 · FY2021 · AI · contact PI
Development of an anti-idiotype based vaccine for respiratory syncytial virus$188,029
R21 · FY2021 · AI · contact PI
Development of an anti-idiotype based vaccine for respiratory syncytial virus$75,971
R21 · FY2021 · AI · contact PI
Defining the protective efficacy of antibodies against the EBV gH/gL glycoprotein complex$825,382
R01 · FY2020 · AI · contact PI
Evaluating anti-idiotypic antibodies as novel vaccine candidates against HIV-1$403,397
P01 · FY2020 · AI · contact PI
Defining the protective efficacy of antibodies against the EBV gH/gL glycoprotein complex$765,542
R01 · FY2019 · AI · contact PI
Evaluating anti-idiotypic antibodies as novel vaccine candidates against HIV-1$376,221
P01 · FY2019 · AI · contact PI
Germline-targeting anti-idiotype antibodies as novel HIV-1 immunogens$220,000
R21 · FY2017 · AI · contact PI
Germline-targeting anti-idiotype antibodies as novel HIV-1 immunogens$264,000
R21 · FY2016 · AI · contact PI